IBRX vs URGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: URGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IBRX and URGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IBRX and URGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy. Its lead approved use is in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and the company is pushing label expansions into BCG-naive bladder cancer and lung cancer while building out global commercial partnerships across roughly 33 to 34 countries. The founder and largest shareholder, Patrick Soon-Shiong, remains central to the story and its strategy.

Full IBRX guide

UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. Its core technology is RTGel, a reverse-thermal hydrogel that is liquid when cold and turns to gel at body temperature, which lets a chemotherapy agent sit against tumor tissue in the bladder or upper urinary tract long enough to work. Two products built on it are approved. Jelmyto, cleared in 2020, treats low-grade upper tract urothelial cancer. Zusduri, cleared in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the first FDA-approved alternative to repeated transurethral resection surgery for that population. Behind them sit UGN-103 (a reformulated follow-on with an NDA targeted for the third quarter of 2026), UGN-104 in upper tract disease, and UGN-501, an oncolytic virus heading into Phase 1. The company had 291 employees as of its latest disclosure and is run by CEO Liz Barrett.

Full URGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IBRX drivers: Anktiva revenue ramp; Label and indication expansion.
• URGN drivers: The Zusduri launch curve; Operating leverage arriving faster than expected.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: IBRX carries the full risk profile of an unprofitable commercial-stage biotech. For URGN, the company still runs a shareholders' deficit of ~$132M with ~$108M of liquidity against ~$189M of term debt and a ~$125M prepaid forward obligation, and its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IBRX if you believe its drivers more; URGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IBRX and URGN guides.

IBRX. The valuation is striking: a multi-billion-dollar market value against roughly ~$113M of trailing revenue implies a very high price-to-sales multiple and prices in significant future growth. The company is not profitable and funds ongoing losses partly through financing, so cash runway and dilution are central to the story. These figures are as of JULY 2026 and shift with each quarterly report and any capital raise.

URGN. There is no meaningful P/E because UroGen is still loss-making on a trailing basis, roughly ~$98M of net loss over the last twelve months, so the shares are usually framed on sales multiples and on how quickly the Zusduri ramp closes the gap. About ~$2.3B of market value against ~$189M of trailing revenue is roughly 12x sales, but annualising the June quarter at ~$290M brings it closer to 8x, and the two numbers are far apart precisely because the product launched in mid-2025. Adding net debt of roughly $206M pushes enterprise value near ~$2.5B, so the balance sheet is not a rounding error here the way it is for a cash-rich clinical-stage biotech.

Headline figures (approximate, JULY 2026): IBRX shows revenue (fy2025) ~$113M net product revenue, revenue growth (q1 2026 yoy) ~168%, q1 2026 net product revenue ~$44M, cash and marketable securities (mar 31, 2026) ~$381M; URGN shows market cap ~$2.3B (~$47 per share, ~48.9M shares), revenue (ttm) ~$189M, revenue (q2 2026) ~$72.5M, vs ~$24.2M a year earlier, net loss (q2 2026) ~$14.4M, or ~$0.28 per share.

IBRX and URGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IBRX and URGN exposure against your real portfolio. It is not an investment adviser.